 I'm frankly surprised even, you know, having set it up. Well, keep in mind, though, Brian, remember last year for biotech and biopharma was horrible. 2023, actually part of 2022 was horrible in terms of even at the JPMorgan Chase conference this year for biopharma, they basically said good times are here coming, but don't expect to raise any money for the first quarter of 2024, which is exactly what happened. And the problem is when you invest in a biopharma firm, it's a venture capital deal. A venture capital deal is typically a seven-year exit.